Vimian

Improvinganimalhealthforbetterlives

Copy link

Vimian is a global animal health company with a passion for making a positive impact through offering animals the best available care. The Group puts science, technology and its customers’ needs at the centre, aiming to deliver effective solutions to animals and veterinary professionals around the world.

During the period between 2015-2018, Fidelio acquired Nextmune, Indical, VetFamily and Movora - four prominent companies within the animal health market, each specialising in their respective niche markets, namely Speciality Pharma, Diagnostics, Veterinary Services and MedTech. In 2021, recognising an attractive opportunity to accelerate continued organic growth as well as to improve collaborative efforts, Fidelio made the strategic decision to gather all four businesses under a shared umbrella, with the foundation of Vimian – a global group of leading niche animal health companies.

In June 2021, Vimian was listed on the Stockholm Stock Exchange, with Fidelio maintaining its role as an active and supportive majority owner.

Company info

CEO

Patrik Ericsson

Head Office

Stockholm, Sweden

Employees

1,100

Acquisition year

2015

Industry

Animal health

Website

vimian.com

80X

Revenue growth

50X

Increase in # employees

50+

Companies added

Thewhy

Having successfully created AniCura in 2011, today part of Mars Petcare and representing one of the largest pet care and pet clinic chains in Europe, Fidelio decided to leverage its gained insights into the broader animal health industry. The journey started with investments in innovation-driven and entrepreneurial businesses within attractive sub-segments of animal health, with the ambition to combine these and establish global category leaders. At the time, many of these sub-segments were highly fragmented and served mainly by smaller, entrepreneurial businesses with limited capabilities to scale. On the other hand, they were also characterised by relatively high entry barriers and strong profitability, supported by scalable business models and IP/patent protection.

Thehow

Vimian’s story begins in 2015 with Fidelio acquiring Artuvet Animal Health B.V., a provider of pet allergy diagnostics and treatment. Since then, Fidelio has, in collaboration with strong entrepreneurs and management teams of companies within Diagnostics(Indical Bioscience), Veterinary Services (VetFamily), and MedTech (Movora) targeting the companion and production animal health market, continued to build what today is known as Vimian – a global and diversified Group operating in four fast-growing animal health verticals.

Strategicinitiatives

Create an ecosystem for ambitious entrepreneurs

Since inception, Vimian has partnered with numerous companies globally.

Geographic expansion

Today, Vimian sells its products and services to countries across the world.

Enable the entrepreneurs

Combine the strengths and capabilities of a global Group with the intimacy, speed, and creativity of an owner-led business.

Thefuturepotential

Following the successful listing of Vimian on the Stockholm Stock Exchange in June 2021, with Fidelio retaining its role as an active majority owner, Vimian has continued to grow through an ambitious strategy across all businesses and verticals.